EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Identifying care gaps along the HIV treatment failure cascade: A multistate analysis of viral load monitoring, re-suppression, and regimen switches in Zambia

Kombatende Sikombe iD, Noelle Le Tourneau iD, Brian Rice iD, Jake M Pry iD, Sandra Simbeza, Laura K Beres iD, Anjali Sharma, Njekwa Mukamba iD, Alison Wringe, James R Hargreaves, Jacob Mutale iD, Carolyn Bolton Moore iD und 3 weitere

PLOS Medicine · 2025

DOI: 10.1371/journal.pmed.1004720 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Medicine, 2025. Verfasst von Kombatende Sikombe und 14 weiteren Autor:innen. Beteiligte Einrichtung: Implementation Science Unit, Centre for Infectious Disease Research in Zambia, Lusaka, Zambia. Hauptthemen laut MEDLINE: HIV Infections, Viral Load, Anti-HIV Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gates Foundation, NIAID NIH HHS, Bill and Melinda Gates Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Timely response to treatment failure is critical for improved outcomes and viral re-suppression among people living with HIV, but care gaps along the treatment failure cascade can occur due to delays by both clients (e.g., retention and adherence) and health systems (e.g., fidelity to viral load [VL] monitoring guidelines). We used multistate analysis to identify drivers of implementation gaps in the treatment failure cascade, including time to HIV VL monitoring, re-suppression, and regimen switches, in Zambia. Methods and findings We used national electronic HIV health records to identify adults on antiretroviral therapy (ART) for more than 6 months who experienced treatment failure (VL ≥ 1,000 copies/ml) at 24 clinics in Lusaka, Zambia, between August 2019 and November 2021. Using multistate analyses, we examined how care evolved after treatment failure, accounting for transitions across the treatment failure cascade over time, such as return visits, repeat VL testing, treatment interruptions (>60 days late for visit), and viral re-suppression. Analyses were stratified by ART regimen at cohort entry: tenofovir disoproxil fumarate/lamivudine or emtricitabine/dolutegravir TDF/XTC/DTG (TLD) and tenofovir disoproxil fumarate/lamivudine or emtricitabine/efavirenz TDF/XTC/EFV (TLE). We repeated analyses to assess switch to second-line therapy among those with consecutively unsuppressed VL test results who were due for regimen switch. Among 179,855 individuals on ART (143,857 with documented VL), 7,916 (4.4%) had a documented elevated VL and drug regimen at the time of treatment failure (52.3% female, median age was 36.7 years (IQR 29.9–43.6), median time on ART 3.3 years (IQR 1.7–6.6), 54.6% on TLD and 45.4% on TLE). Among those with treatment failure, 72.2% (CI 71.3, 73.0%) had returned to clinic 6 months after initial elevated VL was drawn. After one year, 70.1% (CI 69.3, 70.9%) had a repeat VL, 16.6% (CI 15.9, 17.2%) experienced treatment interruption, and 11.4% (CI 10.3, 12.4%) returned to care without repeat VL testing. Among those with a repeat VL, 85.0% (CI 83.9, 86.1%) on TLD and 58.2% (CI 56.8, 59.8%) on TLE had resuppressed. Among those due for second-line switch, 27.9% (CI 24.1, 31.5%) on TLD and 66.6% (CI 64.5, 68.9%) on TLE had changed regimens after one year while 52.4% on TLD had a third VL repeated prior to switch (CI 47.2, 57.4%) (68.0% CI 61.6, 75.2% suppressed of those with repeated VL) compared to 32.1% (CI 29.9, 34.1%) (40.7% CI 36.1, 45.4% suppressed) on TLE. This study was limited by the inability to capture all aspects of care delivery related to treatment failure, such as outreach, enhanced adherence counseling confirmation, and provider rationale for delayed VL rechecking.

Conclusion

After treatment failure, we identified substantial delays in returning for adherence counseling, treatment interruptions, and missed opportunities in rechecking VL status or switching to second-line therapy in routine care in Zambia. Among those who did have VL tests rechecked, re-suppression rates were significantly higher among individuals on TLD compared to TLE. To optimize response and outcomes after treatment failure, strategies must prioritize and target both client and health systems behaviors to meet the care needs in the modern era of TLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsViral LoadAnti-HIV AgentsHumansZambiaTreatment FailureAdultFemaleMaleMiddle Aged

Substanzen

Anti-HIV Agents

Autor:innen und Institutionen

  • Implementation Science Unit, Centre for Infectious Disease Research in Zambia, Lusaka, Zambia.
  • Department of Public Health Environments and Society, Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • Division of Infectious Diseases, Washington University School of Medicine, St Louis, Missouri, United States of America.
  • Sheffield Centre for Health and Related Research (SCHARR), School of Medicine and Population Health, University of Sheffield, Sheffield, United Kingdom.
  • Department of Public Health Sciences, School of Medicine, University of California, Davis, California, United States of America.
  • Department of International Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, United States of America.

ORCID-Profile: Kombatende Sikombe, Noelle Le Tourneau, Brian Rice, Jake M Pry, Laura K Beres, Njekwa Mukamba, Jacob Mutale, Carolyn Bolton Moore, Izukanji Sikazwe, Aaloke Mody

Förderung

  • Gates Foundation
  • NIAID NIH HHS
  • Bill and Melinda Gates Foundation
  • National Institutes of Health

Zitieren

APA

Sikombe, K., Le Tourneau, N., Rice, B., Pry, J. M., Simbeza, S., Beres, L. K., Sharma, A., Mukamba, N., Wringe, A., Hargreaves, J. R., Mutale, J., Moore, C. B., Sikazwe, I., Geng, E., & Mody, A. (2025). Identifying care gaps along the HIV treatment failure cascade: A multistate analysis of viral load monitoring, re-suppression, and regimen switches in Zambia. PLOS Medicine. https://doi.org/10.1371/journal.pmed.1004720

Vancouver

Sikombe K, Le Tourneau N, Rice B, Pry JM, Simbeza S, Beres LK, et al. Identifying care gaps along the HIV treatment failure cascade: A multistate analysis of viral load monitoring, re-suppression, and regimen switches in Zambia. PLOS Medicine. 2025. doi:10.1371/journal.pmed.1004720

BibTeX
@article{Sikombe2025,
  author = {Sikombe, Kombatende and Le Tourneau, Noelle and Rice, Brian and Pry, Jake M and Simbeza, Sandra and Beres, Laura K and Sharma, Anjali and Mukamba, Njekwa and Wringe, Alison and Hargreaves, James R and Mutale, Jacob and Moore, Carolyn Bolton and Sikazwe, Izukanji and Geng, Elvin and Mody, Aaloke},
  title = {Identifying care gaps along the HIV treatment failure cascade: A multistate analysis of viral load monitoring, re-suppression, and regimen switches in Zambia},
  journal = {PLOS Medicine},
  year = {2025},
  doi = {10.1371/journal.pmed.1004720}
}
Kostenlos starten →